...
search icon
nktx-img

Nkarta Inc, Common Stock

NKTX

NSQ

$2.21

+$0.09

(4.25%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$155.96M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
671.09K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.87
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.96 L
$16.24 H
$2.21

About Nkarta Inc, Common Stock

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameNKTXSectorS&P500
1-Week Return1.84%-0.03%1.53%
1-Month Return-4.56%4.75%
3-Month Return-18.15%1.29%2.77%
6-Month Return-56.92%-3.54%12.18%
1-Year Return-78.51%1.59%22.34%
3-Year Return-77.9%13.55%38.91%
5-Year Return-95.39%40.85%80.7%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue115.39K385.00---[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.33,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue17.22K1.05M2.12M6.57M5.87M[{"date":"2019-12-31","value":0.26,"profit":true},{"date":"2020-12-31","value":15.95,"profit":true},{"date":"2021-12-31","value":32.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.3,"profit":true}]
Gross Profit98.17K(1.05M)(2.12M)(6.57M)(5.87M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-1067.56,"profit":false},{"date":"2021-12-31","value":-2162.62,"profit":false},{"date":"2022-12-31","value":-6694.65,"profit":false},{"date":"2023-12-31","value":-5978.53,"profit":false}]
Gross Margin85.08%(272207.79%)---[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-319948.42,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses22.46M51.51M86.43M118.95M131.65M[{"date":"2019-12-31","value":17.06,"profit":true},{"date":"2020-12-31","value":39.12,"profit":true},{"date":"2021-12-31","value":65.65,"profit":true},{"date":"2022-12-31","value":90.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(22.35M)(51.51M)(86.43M)(118.95M)(131.65M)[{"date":"2019-12-31","value":-2234853000,"profit":false},{"date":"2020-12-31","value":-5150800000,"profit":false},{"date":"2021-12-31","value":-8642900000,"profit":false},{"date":"2022-12-31","value":-11895500000,"profit":false},{"date":"2023-12-31","value":-13165000000,"profit":false}]
Total Non-Operating Income/Expense1.10M(39.54M)724.00K10.71M27.69M[{"date":"2019-12-31","value":3.99,"profit":true},{"date":"2020-12-31","value":-142.8,"profit":false},{"date":"2021-12-31","value":2.61,"profit":true},{"date":"2022-12-31","value":38.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(21.08M)(91.36M)(86.08M)(113.84M)(117.50M)[{"date":"2019-12-31","value":-2107583500,"profit":false},{"date":"2020-12-31","value":-9136100000,"profit":false},{"date":"2021-12-31","value":-8607500000,"profit":false},{"date":"2022-12-31","value":-11383700000,"profit":false},{"date":"2023-12-31","value":-11750100000,"profit":false}]
Income Taxes1.81M(40.95M)(2.13M)5.59M5.30M[{"date":"2019-12-31","value":32.36,"profit":true},{"date":"2020-12-31","value":-732.86,"profit":false},{"date":"2021-12-31","value":-38.05,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.85,"profit":true}]
Income After Taxes(22.88M)(50.41M)(83.95M)(119.42M)(122.80M)[{"date":"2019-12-31","value":-2288389800,"profit":false},{"date":"2020-12-31","value":-5040900000,"profit":false},{"date":"2021-12-31","value":-8394900000,"profit":false},{"date":"2022-12-31","value":-11942500000,"profit":false},{"date":"2023-12-31","value":-12280100000,"profit":false}]
Income From Continuous Operations(21.08M)(91.36M)(86.08M)(113.84M)(122.33M)[{"date":"2019-12-31","value":-2107583500,"profit":false},{"date":"2020-12-31","value":-9136100000,"profit":false},{"date":"2021-12-31","value":-8607500000,"profit":false},{"date":"2022-12-31","value":-11383700000,"profit":false},{"date":"2023-12-31","value":-12232900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(22.88M)(50.41M)(83.95M)(119.42M)(117.50M)[{"date":"2019-12-31","value":-2288389800,"profit":false},{"date":"2020-12-31","value":-5040900000,"profit":false},{"date":"2021-12-31","value":-8394900000,"profit":false},{"date":"2022-12-31","value":-11942500000,"profit":false},{"date":"2023-12-31","value":-11750100000,"profit":false}]
EPS (Diluted)-(7.76)(2.62)(2.65)(2.32)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-776,"profit":false},{"date":"2021-12-31","value":-262,"profit":false},{"date":"2022-12-31","value":-265,"profit":false},{"date":"2023-12-31","value":-232,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NKTX
Cash Ratio 12.60
Current Ratio 12.91

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NKTX
ROA (LTM) -16.96%
ROE (LTM) -30.40%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NKTX
Debt Ratio Lower is generally better. Negative is bad. 0.19
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.81

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NKTX
Trailing PE NM
Forward PE NM
P/S (TTM) 1000000.00
P/B 0.35
Price/FCF NM
EV/R 1000000.00
EV/Ebitda 0.95

FAQs

What is Nkarta Inc share price today?

Nkarta Inc (NKTX) share price today is $2.21

Can Indians buy Nkarta Inc shares?

Yes, Indians can buy shares of Nkarta Inc (NKTX) on Vested. To buy Nkarta Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NKTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Nkarta Inc be purchased?

Yes, you can purchase fractional shares of Nkarta Inc (NKTX) via the Vested app. You can start investing in Nkarta Inc (NKTX) with a minimum investment of $1.

How to invest in Nkarta Inc shares from India?

You can invest in shares of Nkarta Inc (NKTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in NKTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Nkarta Inc shares
What is Nkarta Inc 52-week high and low stock price?

The 52-week high price of Nkarta Inc (NKTX) is $16.24. The 52-week low price of Nkarta Inc (NKTX) is $1.96.

What is Nkarta Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Nkarta Inc (NKTX) is 0.35

What is the Market Cap of Nkarta Inc?

The market capitalization of Nkarta Inc (NKTX) is $155.96M

What is Nkarta Inc’s stock symbol?

The stock symbol (or ticker) of Nkarta Inc is NKTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top